X-TOLE2_XPF-010-301: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Grants and Contracts Details

StatusActive
Effective start/end date7/24/237/24/25

Funding

  • Xenon Pharmaceuticals Incorporated: $32,649.00